A pilot trial of hyperfractionated thoracic radiation therapy with concurrent cisplatin and oral etoposide for locally advanced inoperable non- small-cell lung cancer: A 5-year follow-up report

International Journal of Radiation Oncology Biology Physics

Volumn 42, Issue 3, 1998, Pages 479-486

  Lee, Jin S ^a   Komaki, Ritsuko ^a   Fossella, Frank V ^a   Glisson, Bonnie S ^a   Hong, Waun K ^a   Cox, James D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemotherapy; Cisplatin; Concurrent; Hyperfractionated radiation therapy; Non small cell lung cancer; Oral Etoposide; Radiotherapy

Indexed keywords

CISPLATIN; ETOPOSIDE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; ESOPHAGITIS; FEMALE; FEVER; HUMAN; INOPERABLE CANCER; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; MULTIMODALITY CANCER THERAPY; NEPHROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; OTOTOXICITY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA; SKIN TOXICITY;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; PILOT PROJECTS; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT FAILURE;

EID: 0031785105     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00247-8     Document Type: Article

References (40)

1. Dillman RO, Seagren SL, Propert KL, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer N Engl J. Med 1990; 323:940-945.
2. LeChevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and raditherapy in non-resectable non-small cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991; 83:417-423.
3. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer [see comments]. N Eng J Med 1992; 326:524-530.
4. Bleehen NM, Ball D, Belani CP, et al. Combined radiation and chemotherapy for unresectable non-small cell lung carcinoma. Lung Cancer 1994; 10 (Suppl. 1):S19-23.
5. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG 88-08) and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable, non-small cell lung cancer. J Natl Cancer Inst 1995; 87:198-205.
6. Perez CA, Pajak TF, Rubin P, et al. Long-term observations of patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the RTOG. Cancer 1987; 59:1874-1881.
7. Komaki R, Scott CB, Sause WT, et al. Induction cisplatin/ vinblastine and irradiation vs. irradiation in unresectable squamous veil lung lung cancer - failure patterns by cell type in RTOG 88-08/ECOG 4588. Int J Radiat Oncol Biol Phys. 1997;39:537-544.
8. Minna JD, Higgins GA, Glastein EJ. Canbcer of the Lung. In: DeVita VT Jr., Hellman S, Rosen berg SA, editors. Cancer: Principles and Practice of Oncology. 2nd ed. Philadelphia: JB Lippincott C.; 1986:507-597.
9. Jeremic B, Shibamoto Y, Acimovic L, et al. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer. J Clin Oncol 1995; 13:452-458.
10. Lee JS, Scott C, Komaki R, et al. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation Therapy Oncology Group protocol 91-06. J Clin Oncol 1996; 14:1055-1064.
11. Komaki R, Scott C, Ettinger D, et al. Randomized study of chemotherapy radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer - Radiation Therapy Oncology Group (RTOG) 92-04. Int J Radiat Oncol Biol Phys 1997; 38:149-155.
12. Schabel FM, Trader MW, Laster WRJ, et al. Cis-dichlorodiammine paltinum (II). Combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 1979; 63:1459-1473.
13. Sierocki JS, Hilaris BS, Hopfan S, et al. cis-Dichlorodiammineplatinum (II) and VP-16-213: An active induction regimen for small cell carcinoma of the lung. Cancer Treat Rep 1979; 63:1593-1597.
14. Goldhirsch A, Joss RA, Cavalli F, et al. Cis-dichlorodiammineplatinum (II) and VP 16-213 combination chemotherapy for non-small cell lung cancer. Med Pediatr Oncol. 1981; 9:205-208.
15. Longeval E, Klastersky J. Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. A study by the EORTC lung cancer working party (Belgium). Cancer 1982; 50:2751-2756.
16. Evans WK, Feld R, Osoba D, et al. VP-16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer. Cancer 1984; 53:1461-1466.
17. Bosl GJ, Yagoda A, Whitmore WF Jr, et al. VP-16-213 and cisplatin in the treatment of patients with refractory germ cell tumors. Am J Clin Oncol 1984; 7:327-330.
18. Richmond RC, Zimbrick JD, Hykes DL. Radiation-induced DNA damage and lethality in E. coli as modifed by the anitumor agent cis-dichlorodiammineplatinum (II). Radiat Res 1997; 71:447-460.
19. Douple EB, Richmond RC. Enhancement of the potentiation of radiotherapy by platinum drugs in a mouse tumor, Int J Radiat Oncol Biol Phys 1982; 8:501-503.
20. Evans HH, Ricanati M, Horng MF, et al. Relationship between topoisomerase II and radiosensitivity in mouse L5178Y lymphoma strains. Mutat Res 1989; 217:53-63.
21. Slevin ML, Clark PI, Joel SP, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 1989; 7:1333-1340.
22. Hainsworth JD, Johnson DH, Frazier SR, et al. Chronic daily administration of oral etoposide - A phase I trial. J Clin Oncol 1989; 7:396-401.
23. Einhorn LH, Pennington K, McClean J. Phase II trial of daily oral VP-16 in refractory small cell lung cancer: A Hoosier Oncology Group Study. Semin Oncol 1990; 17:32s-35s.
24. Johnson DH, Strupp J, Greco FA, et al. Prolonged administration of daily oral VP-16 in previously treated small cell lung cancer patients: A phase II trial. Proc Am Soc Clin Oncol 1990; 9:227.
25. Waits TM, Johnson DH, Hainsworth JD, et al. Prolonged administration of oral etoposide in non-small-cell lung cancer: A phase II trial. J Clin Oncol 1992; 10:292-296.
26. Mountain CF. A new international staging system for lung cancer. Chest 1986; 89:225s-233.
27. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
29. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50:163-170.
30. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer [see comments]. J Natl Cancer Inst 1994; 86:673-680.
31. Weiden PL, Piantadosi S. Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small-cell lung cancer: A phase II study of the Lung Cancer Study Group. J Natl Cancer Inst 1991; 83:266-273.
32. Strauss GM, Herndon JE, Sherman DD, et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: Report of a Cancer and Leukemia Group B phase II study. J Clin Oncol 1992; 10:1237-1244.
33. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest raditherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995; 13:1880-1892.
34. Cox JD, Azarnia N, Byhardt RW, et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 70.2 Gy: Possible survival benefit with 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: Report of Radiation Therapy Oncology Group 83-11. J Clin Onol 1990; 8:1543-1555.
35. Shaw EG, McGinnis WL, Jett JR, et al. Pilot study of accelerated hyperfractionated thoracic radiation therapy plus concomitant etoposide and cisplatin chemotherapy in patients with unresectable stage III non-small-cell carconoma of the lung. J Natl Cancer Inst 1993; 85:321-323.
36. Choy H. DeVore RF III, Hande KR, et al. Preliminary Preliminary analysis of a phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung cancer. Semin Oncol 1997; 24:S12-26.
37. Martel MK, Ten Haken RK, Hazuka MB, et al. Dose-volume histogram and 3-D treatment planning evalua;tion of patients with pneumonitis, Int J Radiat Oncol Biol Phys 1994; 28:575-581.
38. Sause W, Kolesar P, Taylor S, et al. Five-year results; Phase III trial of regionally advanced unresectable nonsmall cell lung cancer, RTOG 8808, ECOG 4588, SWOG 8992. Proc Am Soc Clin Oncol 1998; 17:453a.
39. Bonner JA, McGinnis WL, Stella PJ, et al. The possible advantage of hyperfractionated thoracic radiotherapy in hte treatment of locally advanced nonsmall cell lung carcinoma: Results of a North Central Cancer Treatment Group PHase III Study. Cancer 1998; 82:1037-1048.
40. Turrisi A, Kim K, Sause W, et al. Observations after 5 year follow-up of intergroup trial 0096: 4 cycle of cisplatin (P) etoposide (E) and concurrent 45 Gy thoracic radiotherapy (TRT) given in daily (QD) or twice-daily fractions followed by 25 Gy PCI. Survival differences and patterns of failure. Proc Am Soci Clin Oncol 1998; 17:457a.